Education
About Us
Working with TipRanks
Follow Us
Abbvie (ABBV)
:ABBV
Earnings Data
Report Date
Feb 04, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
3.36Last Year’s EPS
2.16Same Quarter Last Year
Moderate Buy
Based on 23 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
AbbVie's earnings call reflects a strong overall performance with significant growth in key therapeutic areas like immunology and neuroscience. Financial results exceeded expectations, and the company raised its full-year outlook. However, challenges persist in the aesthetics segment and Humira's sales erosion due to biosimilar competition. Despite these challenges, the company's robust pipeline and increased R&D investment underline a positive long-term outlook.Company Guidance
Strong Financial Performance
AbbVie reported adjusted earnings per share of $1.86, $0.10 above guidance midpoint, and total net revenues of nearly $15.8 billion, reflecting high single-digit sales growth and beating expectations by $300 million.
Robust Growth in Immunology
Skyrizi and Rinvoq, leading immunology medicines, achieved combined sales growth of more than 40%. Skyrizi global sales were $4.7 billion (46% operational growth) and Rinvoq global revenues were nearly $2.2 billion (34.1% operational growth).
Neuroscience Segment Success
Neuroscience, AbbVie's second-largest and fastest-growing therapeutic area, delivered more than $2.8 billion in revenues, a 19.6% operational increase. The migraine portfolio achieved robust double-digit growth, with Qulipta becoming the #1 CGRP treatment for migraine prevention.
Increased R&D Investment
AbbVie anticipates $9 billion in adjusted R&D expenses in 2025, supporting 90 pipeline programs across all stages of development, including new product approvals and expanded indications.
Dividend Increase
AbbVie announced a 5.5% increase in its quarterly cash dividend, payable in February 2026, marking a more than 330% increase since inception.
ABBV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABBV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 31, 2025 | $228.20 | $218.04 | -4.45% |
Jul 31, 2025 | $187.96 | $187.67 | -0.15% |
Apr 25, 2025 | $177.54 | $183.15 | +3.16% |
Jan 31, 2025 | $171.32 | $179.36 | +4.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abbvie (ABBV) report earnings?
Abbvie (ABBV) is schdueled to report earning on Feb 04, 2026, Before Open (Confirmed).
What is Abbvie (ABBV) earnings time?
Abbvie (ABBV) earnings time is at Feb 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABBV EPS forecast?
ABBV EPS forecast for the fiscal quarter 2025 (Q4) is 3.36.
